Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : SIFI
Deal Size : Undisclosed
Deal Type : Merger
SIFI Merges into Faes Farma to Expand International Access to its Portfolio and Pipeline
Details : The Group will invest into the further development of Akantior (polihexanide) into existing and new geographies, as well as the development of polihexanide into additional orphan indications.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 10, 2025
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : SIFI
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2023
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocortisone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Dynamic Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
March 29, 2023
Lead Product(s) : Hydrocortisone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Dynamic Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercialisation of the product in the US following approval.
Product Name : Bilaxten
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 20, 2021
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Bilastine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Dynamic Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 23, 2021
Lead Product(s) : Bilastine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Dynamic Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Calcifediol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 03, 2021
Lead Product(s) : Calcifediol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Potassium Chloride,Ascorbic Acid,Sodium Chloride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Recipient : Norgine
Deal Size : Undisclosed
Deal Type : Agreement
Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU
Details : Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
December 02, 2020
Lead Product(s) : Potassium Chloride,Ascorbic Acid,Sodium Chloride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : Norgine
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Bilastine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2018
Lead Product(s) : Bilastine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bilastine
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2017
Lead Product(s) : Bilastine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bilastine
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Recipient : Charite University, Berlin, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
Bilastine Updosing - Characterization of Underlying Mechanisms
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2011
Lead Product(s) : Bilastine
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Recipient : Charite University, Berlin, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable